OABI
NASDAQ
$2.08
OmniAb Inc (OABI)
OmniAb Inc. is an innovative biotechnology company dedicated to the development of fully human therapeutic antibodies via its advanced OmniAb platform. This proprietary technology enables the rapid identification and optimization of effective therapies across various disease areas, thereby enhancing the likelihood of successful clinical outcomes. By establishing strategic partnerships and collaborations, OmniAb streamlines its drug development processes and improves access to groundbreaking treatments. Supported by a seasoned leadership team and a robust pipeline of product candidates, the company is strategically positioned to capitalize on the growing opportunities within the biopharmaceutical industry.
This company is also listed under the following ticker: OABIW.
Website: https://www.omniab.comSector:
Healthcare
Industry:
Biotechnology
Buy
Target: $7.33 (+252.40%)
Market Cap
$301M
Free Cash Flow Yield
-8.64%
Beta (5Y)
1.08
Price Chart
Valuation
Market Cap$301M
P/S10.42
P/B1.19
Profitability
Total Revenue (TTM)$29M
Gross Profit (TTM)$29M
EBITDA-$40M
Profit Margin-53.4%
Operating Margin-54.3%
EPS-$0.40
Financial Health
Free Cash Flow Yield-8.64%
Growth & Risk
Beta (5Y)1.08
Sharpe Ratio0.34